BioSpace News Archive

Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced the pricing of its initial public offering of 9,828,017 shares of its common stock at a price to the public of $18.00 per share.

Aon plc (NYSE: AON) today reported results for the three and twelve months ended December 31, 2020.

Fourth quarter 2020 revenues increased 30% to $2.42 billion versus fourth quarter 2019 (4) Fourth quarter 2020 EYLEA ® U.S. net sales increased 10% to $1.34 billion versus fourth quarter 2019 and full year 2020 EYLEA U.S. net sales increased 7% versus 2019

Cardinal Health (NYSE: CAH) today reported second-quarter fiscal year 2021 revenue of $41.5 billion, an increase of 5% from the second quarter of last year. Second-quarter GAAP operating earnings increased 38% to $461 million, primarily due to the beneficial comparison to the prior-year charge related to voluntary surgical gown recalls.

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that it has executed a securities purchase agreement to raise gross proceeds of $150 million resulting from the sale of 24,115,755 shares through a private investment in public equity (PIPE) financing at a price of $6.22 per share.

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced plans to showcase the CareDx Cellular Transplant Therapies portfolio at the Transplantation and Cellular Therapy Meeting (TCT) February 8-12, 2021.

REGENXBIO Inc. (Nasdaq: RGNX) today announced that two oral presentations will be presented at the Angiogenesis, Exudation, and Degeneration 2021 conference taking place virtually from February 12 to 13, 2021 .

Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Guggenheim’s Virtual Healthcare Talks | 2021 Oncology Day, which will be webcast on Friday, February 12, 2021.

Applied DNA Sciences, Inc. (NASDAQ: APDN) announced today that it will report fiscal 2021 first quarter financial results after market close on Thursday, February 11, 2021. The Company’s management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same day.

ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, announced today that Chris Martin, Chief Executive Officer, will participate in a fireside chat at Guggenheim Healthcare Talks 2021 Oncology Day